Intravitreal (IVT) Injectables
Market
Intravitreal (IVT) Injectables Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Intravitreal (IVT) Injectables Market Size and Growth
The Intravitreal (IVT) Injectables market is experiencing significant growth, driven by increasing prevalence of retinal diseases and advancements in treatment options. As of 2023, the market size is estimated to exceed $7 billion, with a compound annual growth rate (CAGR) projected at over 10% through the coming years.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Regeneron Pharmaceuticals
◍ Bausch & Lomb
◍ Novartis
◍ Allergan
◍ Alimera Sciences
◍ ThromboGenics
◍ Bristol-Myers Squibb
The Intravitreal (IVT) Injectables Market is competitive, involving companies like Regeneron, Bausch & Lomb, Novartis, and Allergan. These firms innovate treatments for retinal diseases, increasing market growth. Sales revenue examples include:
- Regeneron: $8.13 billion (Eylea).
- Novartis: $4.16 billion (Lucentis).
- Allergan: $3.7 billion (Ozurdex).
Request Sample Report
Market Segmentation
By Application
◍ Hospital Pharmacies
◍ Retail Pharmacies
◍ Drug Stores
◍ Mail Order Pharmacies
◍ Others
By Product
◍ Anti-VEGF
◍ Corticosteroids
◍ Antibiotics
◍ Antivirals
◍ Antifungals
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
